Status:
COMPLETED
Effects of Unblocking the Full Potential of Percept PC IPG
Lead Sponsor:
University of Toronto
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Population Size and Eligible Patients: The study will enroll patients with Parkinson's disease (n=30) who had an IPG replacement from Activa PC (older generation of neurostimulator) to Medtronic Perce...
Eligibility Criteria
Inclusion
- Individuals with idiopathic Parkinson's disease who previously underwent DBS surgery.
- Individuals who had IPG replacement from Activa PC to Medtronic PerceptTM PC Neurostimulator as standard-of-care
- Individuals should be able to provide their informed consent
Exclusion
- Cognition impairment (MoCA \< 20/30)
- Patients with severe PD symptoms who are unable to come to the clinic three times within three months (e.g. bedridden patients)
Key Trial Info
Start Date :
September 29 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2024
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT06127771
Start Date
September 29 2023
End Date
November 1 2024
Last Update
November 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Movement Disorders Centre - Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8